Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
PRNewswire (Wed, 25-Feb 4:05 PM ET)
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Globe Newswire (Mon, 12-Jan 10:14 AM ET)
Market Chameleon (Fri, 9-Jan 6:14 AM ET)
Market Chameleon (Thu, 8-Jan 5:29 AM ET)
PRNewswire (Thu, 8-Jan 9:00 AM ET)
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
PRNewswire (Wed, 7-Jan 9:00 AM ET)
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
PRNewswire (Thu, 11-Dec 4:22 PM ET)
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
PRNewswire (Thu, 11-Dec 9:00 AM ET)
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.
As of February 26, 2026, ELVN stock price climbed to $29.62 with 636,537 million shares trading.
ELVN has a beta of 0.95, meaning it tends to be less sensitive to market movements. ELVN has a correlation of 0.04 to the broad based SPY ETF.
ELVN has a market cap of $1.76 billion. This is considered a Small Cap stock.
In the last 3 years, ELVN traded as high as $30.22 and as low as $9.80.
The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ELVN has outperformed the market in the last year with a price return of +47.1% while the SPY ETF gained +17.2%. ELVN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +36.5% and +5.7%, respectively, while the SPY returned +2.4% and -0.4%, respectively.
ELVN support price is $28.14 and resistance is $30.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.
